Tech stocks across the board had a down day Wednesday after a week of consistent gains, and biotech stocks weren't able to escape the decline. The
Dow Jones U.S. Biotech Index
had climbed 15.3% in the week leading up to yesterday's close, before slipping back 3.4% today. The index is up more than 39% since the recent
low on April 4.
"It's similar to what we're seeing in the rest of tech," said Rob Cohen, the co-head of listed trading for
Credit Suisse First Boston
. "People put a lot of money to work over the last week. Buyers are just taking a breather."
fell hard today, losing 11.5% to $40.35.
Human Genome Sciences
lost 6.4% to $68.46 today, while
, a company developing drugs to deal with infectious diseases, fell 6.5% to $54.04.
Nasdaq Biotechnology Index
had added 17.8% during the last week, and 53.2% since April 4, but it fell 3.8% today. Cohen noted that the moves weren't attended by "a lot of volume or heavy selling."
, one of the biggest biotech gainers in the last week, climbing by 34.7%, lost 5.7% today to $41.80.
, which was all over the press last week for its research announcements coming from the
American Society of Clinical Oncology
conference, gained 23.4% in the past week, before losing 5.3% to $47.61 today.
fell 6% to $59.79 today, while
dropped 5.8% to $48.10. The
Nasdaq 100 Index
, which includes a broad range of tech stocks, including biotechs, fell 3.1%.
(AMGN - Get Report)
slipped 1.7% to $65.15.
One biotech notable headed higher today was
, which rose sharply after a positive research report this morning from
. The firm, according to reports, rated Genome Therapeutics a strong buy, saying that the company is "a leader in using pathogen genomes to find anti-infective drugs." The firm also put an $84 price target on the stock. Shares of Genome Therapeutics traded for $13.05 earlier, a gain of 39.5% on the day.